1
|
Kasi A, Gaudel P, Lekkala M, Al-Rajabi R, Saeed A, Sun W, Porter C. A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity. J Oncol Pharm Pract 2023; 29:1951-1956. [PMID: 36883259 DOI: 10.1177/10781552231161822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2023]
Abstract
INTRODUCTION Fluoropyrimidines (FP) are cornerstone drugs in the treatment of gastrointestinal (GI) malignancies. Cardiotoxicity secondary to an FP chemotherapy is a serious complication. There are no standardized guidelines on the treatment of FP induced cardiotoxicity which may result in interruption and even discontinuation of life saving treatment. We present our experience in FP rechallenge using a novel outpatient regimen based on our "up-front" triple agent antianginal protocol. METHODS We report the retrospective study of the patients with suspected FP induced cardiotoxicity. Patients meeting the criteria were selected by C3OD (curated cancer clinical outcomes database) at Kansas University Medical Center (KUMC). We identified all patients with gastrointestinal malignancies who had suspected FP induced cardiotoxicity from January 2015 to March 2022. We then included the patients who were rechallenged with planned fluoropyrimidine regimen utilizing the three drug KU-protocol. We utilized a novel regimen by repurposing the already FDA-approved anti-anginal drugs in a manner that minimizes the risk of hypotension and bradycardia. RESULTS In this retrospective study, 10 patients with suspected fluoropyrimidine induced cardiotoxicity were included from January-2015 to March-2022 at KUMC. Out of 10 patients who were rechallenged utilizing KU-protocol, eight patients (80%) were able to complete the previously planned fluoropyrimidine regimen. None of the patients required ER visits or hospital admission due to cardiac symptoms during the rechallenge utilizing the KU-protocol. CONCLUSIONS Utilizing our novel outpatient regimen, we have successfully and safely allowed re-challenge of FP chemotherapy with good tolerability and completion of the intended course of chemotherapy without recurrent morbidity.
Collapse
Affiliation(s)
- Anup Kasi
- Medical Oncology, The University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Pramod Gaudel
- Hematology-Oncology Physician, Cancer Care Specialists of Illinois, Decatur, USA
| | - Manidhar Lekkala
- Hematology-Oncology Physician, The University of Kansas Cancer Center at St Francis Campus, Kansas, USA
| | - Raed Al-Rajabi
- Medical Oncology, The University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Anwaar Saeed
- Medical Oncology, The University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Weijing Sun
- Medical Oncology, The University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Charles Porter
- Cardiovascular Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA
| |
Collapse
|
2
|
Gaudel P, Brown P, Byrd K. Vanishing Bile Duct Syndrome in the Presence of Hodgkin Lymphoma. Cureus 2022; 14:e26842. [PMID: 35974868 PMCID: PMC9375519 DOI: 10.7759/cureus.26842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/14/2022] [Indexed: 11/22/2022] Open
Abstract
Vanishing bile duct syndrome (VBDS) is an acquired condition characterized by the destruction and loss of intrahepatic bile ducts resulting in cholestasis. VBDS has been described in various conditions including neoplastic and immunologic disorders, infections, hepatic ischemia, and drug toxicity. The diagnosis is confirmed by liver biopsy revealing the loss of interlobular bile ducts in greater than 50% of portal tracts. Prognosis is variable and often unpredictable but appears to be influenced by the etiology of bile duct destruction and overall patient health. VBDS has been described as a rare paraneoplastic process in patients with Hodgkin lymphoma. This case describes a 26-year-old female who presented with a neck mass, jaundice, and pruritus. Initial workup revealed direct hyperbilirubinemia, transaminitis, elevated alkaline phosphatase, and elevated international normalized ratio. She went on to receive a diagnosis of stage II classical Hodgkin lymphoma, nodular sclerosing subtype, and biopsy-proven VBDS. Over the course of chemotherapy, complete metabolic resolution of Hodgkin lymphoma and complete normalization of bilirubin were achieved. She was given gemcitabine and cyclophosphamide as a liver sparing regimen initially with some improvement in liver function tests and a reduction in lymph node volumes. She received six cycles of adriamycin/bleomycin/vinblastine/dacarbazine (ABVD) with complete remission attained after four cycles by positron emission tomography/computed tomography criteria. This report illustrates asafe chemotherapy regimen in the presence of marked liver dysfunction. Workup for VBDS including liver biopsy should be pursued in Hodgkin lymphoma patients with evidence of cholestasis in the absence of extrahepatic bile duct damage or other known etiology of liver injury.
Collapse
|
3
|
Kasi A, Gaudel P, Bennett J, Al-Rajabi RMT, Saeed A, Baranda JC, Sun W, Porter CB. A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e15613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15613 Background: Fluoropyrimidines, such as 5-fluorouracil (5-FU) and capecitabine, are commonly used chemotherapies for solid tumors, and essential for curative intent treatment of colorectal cancer. But sometimes, their use may be limited by cardiac toxicity limiting the possibility of cure in some patients. Cardiotoxicity could be asymptomatic (EKG changes) or manifested as chest pain, arrhythmias, acute coronary syndrome or death. Rechallenging may be daunting and it may result in interruption or even discontinuation of planned chemo. Traditionally, nitrates and/or IV/oral calcium channel blockers (CCB) have been used for management of fluoropyrimidine-induced cardiotoxicity but without much benefit. Ranolazine, an oral antianginal drug approved for chronic angina, diminishes myocardial ischemia by reducing calcium overload caused by inhibition of late sodium current and it does not affect heart rate or blood pressure. Our objective was to evaluate the efficacy of our novel approach using ranolazine with other traditional drugs. Methods: 8 patients (median age 49.5 yrs) with fluoropyrimidine induced cardiotoxicity were retrospectively analyzed. They were rechallenged with the planned fluoropyrimidine regimen with our 3 drug cardioprotective regimen (KU protocol). This included oral Ranolazine 1000mg BID and Amlodipine 2.5 mg daily to start the day before starting 5FU infusion/oral capecitabine and to continue it until the day after completion of infusion/treatment, and Nitroglycerin paste 1 inch every 6 hours starting before infusion and continue until it was completed. These meds were discontinued upon completion of chemo. Results: 8 patients were rechallenged with fluoropyrimidine utilizing KU protocol, 6 patients (75%) were able to complete previously planned fluoropyrimidine regimen. One pt (*) discontinued capecitabine due to recurrent chest pain and treatment was switched to 5FU based regimen with KU protocol, which pt was able to complete without chest pain. Another pt (**), 5FU was stopped due to severe diarrhea, not due to cardiotoxicity. All pts tolerated KU protocol well. Conclusions: In our small, single center experience, we were able to safely and effectively rechallenge pts with fluoropyrimidines and complete curative intent treatment with our KU protocol. This protocol uses FDA approved oral and transcutaneous drugs without requiring a healthcare personnel to administer an IV CCB that can cause precipitous bradycardia and/or hypotension. Our results need validation in a larger cohort. [Table: see text]
Collapse
Affiliation(s)
- Anup Kasi
- University of Kansas Cancer Center, Westwood, KS
| | - Pramod Gaudel
- University of Kansas Medical Center, Kansas City, KS
| | | | | | - Anwaar Saeed
- Kansas University Cancer Center, Kansas City, KS
| | | | - Weijing Sun
- University of Kansas Medical Center, Kansas City, KS
| | | |
Collapse
|
4
|
Gaudel P, Mohyuddin GR, Fields-Meehan J. Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. Fed Pract 2021; 38:89-91. [PMID: 33716486 DOI: 10.12788/fp.0061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Background Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis. First-line multikinase inhibitors like sorafenib and lenvatinib are poorly tolerated and have low response rates. Several clinical trials have shown tolerability and efficacy of immunotherapy in this setting. The objective of this retrospective study was to determine the outcomes of front-line nivolumab in a frail real-world population. Observations In this retrospective study conducted between January 2016 and December 2019, 14 men (median age, 63.5 years; range, 58-72 years) with HCC received nivolumab as front-line systemic therapy. Only 2 patients had a response to immunotherapy (14.3%), of which 1 patient had a complete response (7.1%). The median progression-free survival was 4 months and median overall survival was 8 months. Incidence of grade 3 or higher toxicity was 35%. Conclusions In our small, real-world cohort of patients receiving immunotherapy as front-line systemic treatment for HCC, outcomes were poor with front-line immunotherapy.
Collapse
Affiliation(s)
- Pramod Gaudel
- and are Hematology-Oncology Fellow Physicians, both in the Department of Internal Medicine at The University of Kansas Medical Center in Westwood. is an Attending Physician in the Department of Hematology and Medical Oncology at the Kansas City Veterans Affairs Medical Center in Missouri
| | - Ghulam Rehman Mohyuddin
- and are Hematology-Oncology Fellow Physicians, both in the Department of Internal Medicine at The University of Kansas Medical Center in Westwood. is an Attending Physician in the Department of Hematology and Medical Oncology at the Kansas City Veterans Affairs Medical Center in Missouri
| | - January Fields-Meehan
- and are Hematology-Oncology Fellow Physicians, both in the Department of Internal Medicine at The University of Kansas Medical Center in Westwood. is an Attending Physician in the Department of Hematology and Medical Oncology at the Kansas City Veterans Affairs Medical Center in Missouri
| |
Collapse
|
5
|
Gaudel P, Kaunonen M, Neupane S, Joronen K, Koivisto AM, Rantanen A. Lifestyle related risk factors of coronary artery disease patients in Nepal. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz186.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Coronary Artery Disease (CAD) is a leading cause of morbidity and mortality and serious health problem worldwide. It is important to observe lifestyle related risk factors in patients with CAD for effective planning and implementation of secondary prevention strategies. The aim of this study is to describe the prevalence of lifestyle related risk factor habits among the patients with CAD.
Methods
A cross-sectional study was conducted among CAD patients in a tertiary care national heart center in Kathmandu, Nepal. Six lifestyle related factors (dietary habit, smoking, alcohol consumption, stress, physical activity and adherence to medication) and Body Mass Index were used as the risk factors of CAD in this study. Individual face-to-face structured interview was conducted using culturally validated standard instruments. The descriptive characteristics were presented as frequencies and percentages for categorical variables and as mean ± standard deviation (SD) or median and interquartile range (IQR) otherwise.
Results
In total study population, the mean age of the patients was 59.9 years and 76% were male. Patients having any three risk factors out of seven were the most common (36%) followed by two risk factors (25%) and four risk factors (22%). About 32% of study population were current smokers, whereas 29% were former smokers. Likewise, 31% of the total were physically inactive. Majority of the patients 95% had perceived moderate stress.
Conclusions
The prevalence of lifestyle related risk factors is high among CAD patients in study population. Combination of any three lifestyle related risk factors were the most common among patients. Therefore, studies focusing on lifestyle risk factor modification intervention on particular groups is recommended.
Key messages
Need to improve awareness about lifestyle related risk factors among CAD patients. Highlight the importance of lifestyle counselling.
Collapse
Affiliation(s)
- P Gaudel
- Health Sciences, University of Tampere, Tampere, Finland
| | - M Kaunonen
- Health Sciences, University of Tampere, Tampere, Finland
| | - S Neupane
- Health Sciences, University of Tampere, Tampere, Finland
| | - K Joronen
- Health Sciences, University of Tampere, Tampere, Finland
| | - A M Koivisto
- Health Sciences, University of Tampere, Tampere, Finland
| | - A Rantanen
- Health Sciences, University of Tampere, Tampere, Finland
| |
Collapse
|
6
|
Abstract
Thrombocytopenia is an uncommon side effect of trimethoprim/sulfamethoxazole (TMP/SMX) when given in the usual recommended adult dosage. We report a case of severe and possibly life-threatening thrombocytopenia associated with TMP/SMX therapy. A 92-year-old female presented after a mechanical fall and subsequent intractable bleeding from a laceration on her left leg. She had a history of cellulitis of the lower extremities treated with a 10-day course of TMP/SMX. Her last dose was two days before the visit. The physical examination was significant for a small laceration on her left shin, with persistent oozing of blood. Her blood work was notable for white blood cells (WBC) 9.4×10^9/L (9.4×10^3/mm^3), hemoglobin 125g/L (12.5 g/dL) and platelets 5×10^9/L (5×10^3/mm^3). A repeat platelet count was 4×10^9/L. Prothrombin time was 11 seconds and the international normalized ratio (INR) was one. The TMP/SMX was discontinued and one unit of platelets was transfused. Her platelet count subsequently increased to 108×10^9/L. Severe thrombocytopenia with a platelet count of ≤10×10^9/Lmay rarely result in the catastrophic spontaneous bleeding. Thus, low platelet counts associated with TMP/SMX carry potential life-threatening complications. The clinicians should be aware of this adverse effect of TMP/SMX, which appears to be dose/duration independent. We suggest careful monitoring of complete blood cell count, especially platelet count, before and during TMP/SMX therapy.
Collapse
Affiliation(s)
- Pramod Gaudel
- Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States
| | - Ahmed H Qavi
- Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States
| | - Prasanta Basak
- Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States
| |
Collapse
|
7
|
Ahmad J, Sohail MS, Khan A, Qavi AH, Gaudel P, Zahid M, Assad S. Anti-n-Methyl-d-Aspartate-Receptor (NMDAR) Encephalitis in Association with Ovarian Teratoma. Cureus 2017; 9:e1425. [PMID: 28884051 PMCID: PMC5584997 DOI: 10.7759/cureus.1425] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Anti-N-methyl-D-aspartate-Receptor (NMDAR) encephalitis is an autoimmune disorder with a multifaceted presentation that involves memory deficits, psychiatric symptoms, and autonomic instability. This case report describes the classic presentation of Anti-NMDAR encephalitis and highlights its association with ovarian teratomas. We present a 26 -year-old female who came in with new onset seizures and altered mentation who subsequently developed automatism. Electroencephalograms (EEG) showed left frontal spikes and right temporal delta activity. Magnetic resonance imaging (MRI) revealed right temporal hyper-intensity. The diagnosis was established with positive anti-NMDAR antibodies in the cerebrospinal fluid (CSF). The patient was initially treated with steroids and valproic acid, however, her condition progressively worsened. A five-day course of intravenous immunoglobulins (IVIG) was started followed by rituximab. The clinical course was complicated with the patient developing neutropenic fever and cerebrospinal fluid cultures (CSF) growing methicillin-sensitive Staphylococcus aureus (MSSA). She underwent pelvic imaging which showed a right ovarian teratoma. Evidence suggests that removal of ovarian tumor leads to better clinical and mortality outcomes in patients with Anti-NMDAR encephalitis. It is important for the internist to consider paraneoplastic syndromes in patients with Anti-NMDAR encephalitis.
Collapse
Affiliation(s)
- Javaad Ahmad
- Department of Neurology, Mount Sinai Hospital New York, Usa
| | | | - Amina Khan
- Shifa Tameer E Millat University, Shifa International Hospital, Islamabad, Pakistan
| | | | - Pramod Gaudel
- Department of Medicine, Montefiore New Rochelle Hospital, Albert Einstein College of Medicine, Ny, Usa
| | - Mehr Zahid
- Internal Medicine, University of Lahore, Lahore, Pakistan
| | - Salman Assad
- Department of Medicine, Shifa International Hospital, Islamabad, Pakistan
| |
Collapse
|